A case report of acute kidney injury associated with pegylated recombinant human granulocyte colony-stimulating factor injection

Published on Aug. 13, 2025Total Views: 33 times Total Downloads: 7 times Download Mobile

Author: ZHONG Hong ¹ QIU Hongbo ² ZHANG Xuanyi ¹  KONG Wenqiang ¹

Affiliation: 1. Department of Pharmacy, the First’s Hospital of Zigong City, Zigong 643000, Sichuan Province, China 2. Department of Oncology, the First’s Hospital of Zigong City, Zigong 643000, Sichuan Province, China

Keywords: Pegylated recombinant human granulocyte colony-stimulating factor Acute kidney injury Adverse drug reaction

Abstract
Full-text
References

Abstract

A 58-year-old female patient with breast cancer received treatment with pegylated recombinant human granulocyte colony-stimulating factor (PEG-rhG-CSF) injection after adjuvant chemotherapy. The serum creatinine level of the patient gradually increased from the normal baseline value to 199.3 μmol·L^-1. The patient was diagnosed as acute kidney injury (AKI), after stopping the medication and providing symptomatic treatment, the patient's renal function gradually improved. The patient completed subsequent chemotherapy as planned without reusing PEG-rhG-CSF injection, and other medications and dosages remained unchanged. Renal function remained stable during follow-up. Naranjo’s Assessment Scale was used to evaluate the association between PEG-rhG-CSF injection and AKI, the result was "probable." There are few reports of AKI occuring with PEG-rhG-CSF injection, and this case provides evidence for clinical safe medication.

Full-text

Please download the PDF version to read the full text: download

References

1.Blayney DW, Schwartzberg L. Chemotherapy-induced neutropenia and emerging agents for prevention and treatment: a review[J]. Cancer Treat Rev, 2022, 109: 102427. DOI: 10.1016/j.ctrv.2022.102427.

2.中国抗癌协会肿瘤临床化疗专业委员会, 中国抗癌协会肿瘤支持治疗专业委员会. 肿瘤化疗导致的中性粒细胞减少诊治中国专家共识（2023版）[J]. 中华肿瘤杂志, 2023, 45(7): 575-583. [China Anti-cancer Association Tumor Clinical Chemotherapy Professional Committee, China Anti-cancer Association Tumor Support Therapy Professional Committee. Consensus on clinical diagnosis, treatment, and prevention of chemotherapy-induced neutropenia in China (2023 edition) [J]. Chinese Journal of Oncology, 2023, 45(7): 575-583.] DOI: 10.3760/cma.j.cn112152-20230224-00076.

3.Crawford J, Herndon D, Gmitter K, et al. The impact of myelosuppression on quality of life of patients treated with chemotherapy[J]. Future Oncol, 2024, 20(21): 1515-1530. DOI: 10.2217/fon-2023-0513.

4.Crawford J, Oswalt C. The impact of new and emerging agents on outcomes for febrile neutropenia: addressing clinical gaps[J]. Curr Opin Oncol, 2023, 35(4): 241-247. DOI: 10.1097/CCO. 0000000000000952.

5.Smith TJ, Bohlke K, Lyman GH, et al. Recommendations for the use of WBC growth factors: american society of clinical oncology clinical practice guideline update[J]. J Clin Oncol, 2015, 33(28): 3199-3212. DOI: 10.1200/JCO.2015.62.3488.

6.Crawford J, Moore DC, Morrison VA, et al. Use of prophylactic pegfilgrastim for chemotherapy-induced neutropenia in the US: a review of adherence to present guidelines for usage[J]. Cancer Treat Res Commun, 2021, 29: 100466. DOI: 10.1016/j.ctarc.2021.100466.

7.Aapro M, Boccia R, Leonard R, et al. Refining the role of pegfilgrastim (a long-acting G-CSF) for prevention of chemotherapy-induced febrile neutropenia: consensus guidance recommendations[J]. Support Care Cancer, 2017, 25(11): 3295-3304. DOI: 10.1007/s00520-017-3842-1.

8.中国医师协会放射肿瘤治疗医师分会, 中华医学会放射肿瘤治疗学分会, 中国抗癌协会肿瘤放射治疗专业委员会. 同步放化疗期间应用聚乙二醇化重组人粒细胞刺激因子中国专家共识（2023版）[J]. 国际肿瘤学杂志, 2023, 50(4): 193-201. DOI: 10.3760/cma.j.cn371439-20230227-00039.

9.国家慢性肾病临床医学研究中心, 中国医师协会肾脏内科医师分会, 中国急性肾损伤临床实践指南专家组. 中国急性肾损伤临床实践指南[J]. 中华医学杂志, 2023, 103(42): 3332-3366. [National Clinical Research Center for Kidney Diseases, Chinese Nephrologist Association, Expert Group on AKI Guidelines. Chinese clinical practice guideline for acute kidney injury[J]. National Medical Journal of China, 2023, 103(42): 3332-3366.] DOI: 10.3760/cma.j.cn112137-20230802-00133.

10.Arora S, Bhargava A, Jasnosz K, et al. Relapsing acute kidney injury associated with pegfilgrastim[J]. Case Rep Nephrol Urol, 2012, 2(2): 165-171. DOI: 10.1159/000345278.

11.Elabd H, Nayak R, Rashid T, et al. The Case | Acute kidney injury in a 78-year-old man with low-grade B-cell lymphoma[J]. Kidney Int, 2018, 93(1): 275-276. DOI: 10.1016/j.kint.2017.07.001.

12.Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions[J]. Clin Pharmacol Ther, 1981, 30(2): 239-245. DOI: 10.1038/clpt.1981.154.

13.Vogel CL, Wojtukiewicz MZ, Carroll RR, et al. First and subsequent cycle use of pegfilgrastim prevents febrile neutropenia in patients with breast cancer: a multicenter, double-blind, placebo-controlled phase III study[J]. J Clin Oncol, 2005, 23(6): 1178-1184. DOI: 10.1200/JCO.2005.09.102.

14.马军, 朱军, 徐兵河, 等. 聚乙二醇化重组人粒细胞刺激因子（PEG-rhG-CSF）床应用中国专家共识[J]. 中国肿瘤临床, 2016, 43(7): 271-274. DOI: 10.3969/j.issn.1000-8179.2016.07.239.

15.Curran MP, Goa KL. Pegfilgrastim[J]. Drugs, 2002, 62(8): 1207-1215. DOI: 10.2165/00003495-200262080-00012.

16.Perazella MA, Rosner MH. Drug-induced acute kidney injury[J]. Clin J Am Soc Nephrol. 2022 ,17(8): 1220-1233. DOI: 10.2215/CJN.11290821.

17.Fernandez-Juarez G, Perez JV, Caravaca-Fontán F, et al. Duration of treatment with corticosteroids and recovery of kidney function in acute interstitial nephritis [J]. Clin J Am Soc Nephrol, 2018, 13(12): 1851-1858. DOI: 10.2215/CJN.01390118.